Abstract
One of the important potential adverse reactions of HEMT is hepatobiliary disorders, and regular liver function monitoring is essential practice. This study aims to evaluate the effect of the triple CFTR-modulator therapy Kaftrio (elexacaftor/tezacaftor/ivacaftor) on liver function tests (LFT’s) of patients with cystic fibrosis-related liver disease (PwCFLD) one year after starting therapy.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
